ジプラシドン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H373：長期にわたる、または反復暴露により臓器の障 害のおそれ

• 注意書き

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P272：汚染された作業衣は作業場から出さないこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P314：気分が悪い時は、医師の診断/手当てを受けること。

  P333+P313：皮膚刺激または発疹が生じた場合：医師の診断/手当てを 受けること。

ジプラシドン 価格

ジプラシドン 化学特性,用途語,生産方法

• 外観

  白色～ほとんど白色粉末～結晶

• 効能

  統合失調症治療薬, 神経遮断薬

• 化学的特性

  Tan Solid

• 使用

  Labelled Ziprasidone, which is used as an antipsychotic. Combined serotonin (5HT2) and dopamine (D2) receptor antagonist.

• 定義

  ChEBI: A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.

• 生物学の機能

  "Ziprasidone is chemically similar to risperidone but with a substitution of piperzinyl and benzisothiazole for piperidinyl and benzisoxazole and with minor aromatic modification. Like risperidone, ziprasidone is a high-affinity antagonist at 5-HT2A/C and D2 receptors as well as at adrenergic α1/α2 and histamine H1 receptors. Moreover, ziprasidone can activate 5-HT1A receptors that regulate dopaminergic neurotransmission in brain regions involved in critical cognitive functions. Thus, in addition to D2 partial agonism, 5-HT1A agonism is now thought to be an important pharmacological property for atypical antipsychotic drug efficacy.

• 一般的な説明

  Ziprasidone (Geodon, a benzisothiazolpiprazinylindolonederivative) also has the structuralfeatures of a hybrid molecule between a butyrophenone antipsychoticand a trazodone-like antidepressant. It is highlymetabolized to four major metabolites, only one of which, Smethyldihydroziprasidone,likely contributes to its clinical activity. In humans, less than 5% of the dose isexcreted unchanged. Reduction by aldehyde oxidase accountsfor about 66% of ziprasidone metabolism; two oxidative pathwaysinvolving hepatic CYP3A4 account for the remainder.

• 作用機序

  Ziprasidone (half-life, 6 hours) has an oral bioavailability of approximately 60%, which can be enhanced in the presence of fatty foods. It is extensively metabolized (<5% excreted unchanged) by aldehyde oxidase, which results in reductive cleavage of the S–N bond, and then by S-methylation. Ziprasidone also can undergo CYP3A4-catalyzed N-dealkylation and S-oxidation.

ジプラシドン 上流と下流の製品情報

ジプラシドン 生産企業

Global(242)Suppliers

ジプラシドン スペクトルデータ(¹HNMR)

146939-27-7, ジプラシドン キーワード